Patent ID: 7691392

Claim:
A method of treating multiple myeloma (MM) in a subject in need of such treatment, comprising the step of administering to said subject a pharmaceutical formulation comprising a therapeutically effective dose of 17-allylamino-17-demethoxygeldanamycin (17-AAG) or 17-aminogeldanamycin (17-AG), and optionally a pharmaceutically acceptable carrier or diluent, and optionally repeating said administering step until no further therapeutic benefit is obtained, wherein said therapeutically effective dose is in the range of about 275 to about 420 mg/m 2 of 17-AAG, or an equivalent amount of 17-AG and results in an AUC total of 17-AAG per dose in the range of about 12,500 to about 20,000 ng/mL*h and/or an AUC total of 17-AG per dose in the range of about 5,000 ng/mL*h to about 18,000 ng/mL*h.